Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urological Association Annual Meeting
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) announced today that data from the vibegron EMPOWUR 52-week extension study (NCT03583372) and data by age groups from the 12-week placebo-controlled EMPOWUR study (NCT03492281) will be presented virtually by the authors during the 2020 American Urological Association (AUA) Annual Meeting and will be available for viewing on the annual meeting website, on May 15, 2020. The data sets that will be presented suppo
